Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 6/20 | 1.00 |
| ▸ | GABBR1 | Q9UBS5 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL339757 | 1.00 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP1A2CYP2C9 | |
| SCHEMBL28968674 | 1.00 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP1A2CYP2C9 | |
| SCHEMBL4601734 | 0.81 | GABBR2 (0.69) | GABBR2GABBR1LMNACYP1A2CYP2C9 | |
| SCHEMBL23082612 | 0.78 | GABBR2 (0.64) | GABBR2GABBR1LMNACYP1A2CYP2C9 | |
| SCHEMBL1055044 | 0.78 | GABBR2 (0.64) | GABBR2GABBR1LMNACYP1A2CYP2C9 | |
| SCHEMBL10507284 | 0.78 | GABBR2 (0.64) | GABBR2GABBR1LMNACYP1A2CYP2C9 | |
| SCHEMBL6032624 | 0.78 | GABBR2 (0.64) | GABBR2GABBR1LMNACYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL10681987 | 0.76 | GABBR2 (0.62) | GABBR2GABBR1LMNACYP1A2CYP2C9 | |
| SCHEMBL7396004 | 0.75 | GABBR2 (0.61) | GABBR2GABBR1LMNACYP1A2CYP2C9 | |
| SCHEMBL9779274 | 0.75 | GABBR2 (0.61) | GABBR2GABBR1LMNACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | Sunovion Inc. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8097625-B2 | Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression | SUNOVION PHARMACEUTICALS INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2343073-A2 | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression | Sepracor Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20070299055-A1 | COMBINATION OF SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20050215521-A1 | Modafinil combination therapy for improving sleep quality | SEPRACOR INC. | 2005-09-29 | — | — | US | disclosed |
| US-20050176680-A1 | Eszopiclone stimulates GABA receptors, and serotonin reuptake inhibitor (citalopram), norepinephrine reuptake inhibitor (desipramine), 5-HT2A modulator, or dopamine reuptake inhibitor (amineptine) | SEPRACOR, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| US-20050164987-A1 | Melatonin combination therapy for improving sleep quality | SEPRACOR INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299055-A1 | COMBINATION OF SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | HTR2A, HTR5A, HTR2C | GABBR2 33/4885GABBR1 27/4885LMNA 1965/4885 |
| US-20050176680-A1 | Eszopiclone stimulates GABA receptors, and serotonin reuptake inhibitor (citalopram), norepinephrine reuptake inhibitor (desipramine), 5-HT2A modulator, or dopamine reuptake inhibitor (amineptine) | HTR2A, HTR2C, HTR5A | GABBR2 56/4885GABBR1 48/4885LMNA 2515/4885 |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | HTR2A, HTR5A, HTR2C | GABBR2 25/4885GABBR1 22/4885LMNA 2199/4885 |
| US-20050164987-A1 | Melatonin combination therapy for improving sleep quality | MTNR1A, MTNR1B, CRY1 | GABBR2 287/4885GABBR1 148/4885LMNA 1749/4885 |
| US-20050215521-A1 | Modafinil combination therapy for improving sleep quality | HCRTR2, HCRTR1, MTNR1A | GABBR2 331/4885GABBR1 206/4885LMNA 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.